dc.contributor |
Universitat de Barcelona |
dc.contributor.author |
Tebruegge, Marc |
dc.contributor.author |
Ritz, Nicole |
dc.contributor.author |
Koetz, Karsten |
dc.contributor.author |
Noguera Julian, Antoni |
dc.contributor.author |
Seddon, James A. |
dc.contributor.author |
Welch, Steven B. |
dc.contributor.author |
Tsolia, Maria |
dc.contributor.author |
Kampmann, Beate |
dc.date |
2018-03-28T14:10:12Z |
dc.date |
2018-03-28T14:10:12Z |
dc.date |
2014-06-12 |
dc.date |
2018-03-28T14:10:12Z |
dc.identifier.citation |
1932-6203 |
dc.identifier.citation |
646516 |
dc.identifier.uri |
http://hdl.handle.net/2445/121198 |
dc.format |
6 p. |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Public Library of Science (PLoS) |
dc.relation |
Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0099129 |
dc.relation |
PLoS One, 2014, vol. 9, num. 6, p. e99-e129 |
dc.relation |
https://doi.org/10.1371/journal.pone.0099129 |
dc.rights |
cc-by (c) Tebruegge, Marc et al., 2014 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
http://creativecommons.org/licenses/by/3.0/es |
dc.subject |
Tuberculosi |
dc.subject |
Microbiologia mèdica |
dc.subject |
Diagnòstic molecular |
dc.subject |
Europa |
dc.subject |
Tuberculosis |
dc.subject |
Medical microbiology |
dc.subject |
Molecular diagnosis |
dc.subject |
Europe |
dc.title |
Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in Europe |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molecular and immunological tests for tuberculosis (TB) in the European setting. METHODS: Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-European-Trialsgroup (TBnet) members conducted June to December 2013. Both networks comprise clinicians, microbiologists, epidemiologists and researchers predominately based in Europe. RESULTS: 191 healthcare professionals from 31 European countries participated. Overall, 26.8% of respondents did not have access to the Xpert MTB/RIF assay; only 44.6% had access to the assay in-house. However, a substantial proportion had access to other commercial and/or non-commercial PCR-based assays for TB (68.8% and 31.8%, respectively). Only 6.4% did not have access to any PCR-based assays for TB. A large proportion of participants with access to the Xpert MTB/RIF assay had used it for the analysis of non-respiratory samples [pleural fluid: 36.5%, gastric aspirates: 34.7%, cerebrospinal fluid: 34.7%, stool samples: 4.3%, blood/serum: 2.6%, 'other samples' (which included biopsy/tissue samples, lymph node aspirates, joint aspirates and urine samples): 16.5%]. Regarding interferon-gamma release assays, a greater proportion of respondents had access to the QuantiFERON-TB Gold assay (84.7%) than to the T-SPOT.TB assay (52.2%). CONCLUSIONS: Both immunological and molecular TB tests are widely available across Europe. The QuantiFERON-TB Gold assay is more widely used than the T-SPOT.TB assay, which may reflect the difficulties of integrating an ELISPOT assay into the routine laboratory setting. Although Xpert MTB/RIF assays are optimised and solely licensed for the analysis of sputum samples, in clinical practice they are commonly used for non-respiratory samples. Further research is needed to establish how current molecular TB tests impact on patient care and outcome in the routine clinical setting. |